Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy

Science Translational Medicine

Volumn 6, Issue 226, 2014, Pages

  Zamarin, Dmitriy ^a   Holmgaard, Rikke B ^a   Subudhi, Sumit K ^b   Park, Joon Seok ^c,d   Mansour, Mena ^e   Palese, Peter ^e   Merghoub, Taha ^a   Wolchok, Jedd D ^a,d   Allison, James P ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c ROCKEFELLER UNIVERSITY   (United States)

^d Weill Cornell Graduate School of Biomedical Sciences   (United States)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; INTERFERON; ONCOLYTIC VIRUS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG POTENTIATION; IMMUNOGENICITY; IMMUNOSTIMULATION; INFLAMMATION; LYMPHOCYTIC INFILTRATION; MELANOMA B16; METASTASIS POTENTIAL; MONOTHERAPY; MOUSE; NATURAL KILLER CELL; NEWCASTLE DISEASE PARAMYXOVIRUS; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; VIROGENESIS; VIRUS REPLICATION;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CTLA-4 ANTIGEN; IMMUNE SYSTEM; IMMUNOTHERAPY; INFLAMMATION; INTERFERON TYPE I; KILLER CELLS, NATURAL; LYMPHOCYTES; MELANOMA, EXPERIMENTAL; MICE; NEOPLASM TRANSPLANTATION; NEWCASTLE DISEASE VIRUS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES;

EID: 84897476768     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3008095     Document Type: Article

References (42)

1. K. S. Peggs, S. A. Quezada, J. P. Allison, Cancer immunotherapy: Co-stimulatory agonists and co-inhibitory antagonists. Clin. Exp. Immunol. 157, 9-19 (2009).
2. S. L. Topalian, F. S. Hodi, J. R. Brahmer, S. N. Gettinger, D. C. Smith, D. F. McDermott, J. D. Powderly, R. D. Carvajal, J. A. Sosman, M. B. Atkins, P. D. Leming, D. R. Spigel, S. J. Antonia, L. Horn, C. G. Drake, D. M. Pardoll, L. Chen, W. H. Sharfman, R. A. Anders, J. M. Taube, T. L. McMiller, H. Xu, A. J. Korman, M. Jure-Kunkel, S. Agrawal, D. McDonald, G. D. Kollia, A. Gupta, J. M. Wigginton, M. Sznol, Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443-2454 (2012).
3. F. S. Hodi, S. J. O'Day, D. F. McDermott, R. W. Weber, J. A. Sosman, J. B. Haanen, R. Gonzalez, C. Robert, D. Schadendorf, J. C. Hassel, W. Akerley, A. J. Van Den Eertwegh, J. Lutzky, P. Lorigan, J. M. Vaubel, G. P. Linette, D. Hogg, C. H. Ottensmeier, C. Lebbé, C. Peschel, I. Quirt, J. I. Clark, J. D. Wolchok, J. S. Weber, J. Tian, M. J. Yellin, G. M. Nichol, A. Hoos, W. J. Urba, Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723 (2010).
4. D. R. Leach, M. F. Krummel, J. P. Allison, Enhancement of antitumor immunity by CTLA-4 blockade. Science 271, 1734-1736 (1996).
5. A. Van Elsas, A. A. Hurwitz, J. P. Allison, Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J. Exp. Med. 190, 355-366 (1999).
6. + T cells. Sci. Transl. Med. 5, 200ra116 (2013).
7. R. R. Ji, S. D. Chasalow, L. Wang, O. Hamid, H. Schmidt, J. Cogswell, S. Alaparthy, D. Berman, M. Jure-Kunkel, N. O. Siemers, J. R. Jackson, V. Shahabi, An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol. Immunother. 61, 1019-1031 (2012).
8. + dendritic cells. J. Exp. Med. 208, 2005-2016 (2011).
9. M. S. Diamond, M. Kinder, H. Matsushita, M. Mashayekhi, G. P. Dunn, J. M. Archambault, H. Lee, C. D. Arthur, J. M. White, U. Kalinke, K. M. Murphy, R. D. Schreiber, Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J. Exp. Med. 208, 1989-2003 (2011).
10. S. J. Russell, K. W. Peng, J. C. Bell, Oncolytic virotherapy. Nat. Biotechnol. 30, 658-670 (2012).
11. C. J. Breitbach, J. Burke, D. Jonker, J. Stephenson, A. R. Haas, L. Q. Chow, J. Nieva, T. H. Hwang, A. Moon, R. Patt, A. Pelusio, F. Le Boeuf, J. Burns, L. Evgin, N. De Silva, S. Cvancic, T. Robertson, J. E. Je, Y. S. Lee, K. Parato, J. S. Diallo, A. Fenster, M. Daneshmand, J. C. Bell, D. H. Kirn, Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature 477, 99-102 (2011).
12. J. Heo, T. Reid, L. Ruo, C. J. Breitbach, S. Rose, M. Bloomston, M. Cho, H. Y. Lim, H. C. Chung, C. W. Kim, J. Burke, R. Lencioni, T. Hickman, A. Moon, Y. S. Lee, M. K. Kim, M. Daneshmand, K. Dubois, L. Longpre, M. Ngo, C. Rooney, J. C. Bell, B. G. Rhee, R. Patt, T. H. Hwang, D. H. Kirn, Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat. Med. 19, 329-336 (2013).
13. R. H. Andtbacka, F. A. Collichio, T. Amatruda, N. N. Senzer, J. Chesney, K. A. Delman, L. E. Spitler, I. Puzanov, S. Doleman, Y. Ye, A. M. Vanderwalde, R. Coffin, H. Kaufman. OPTiM: A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocytemacrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma, presented at the 2013 ASCO Annual Meeting, Chicago, IL, 2013.
14. D. Zamarin, L. Martínez-Sobrido, K. Kelly, M. Mansour, G. Sheng, A. Vigil, A. García-Sastre, P. Palese, Y. Fong, Enhancement of oncolytic properties of recombinant Newcastle disease virus through antagonism of cellular innate immune responses. Mol. Ther. 17, 697-706 (2009).
15. S. Elankumaran, V. Chavan, D. Qiao, R. Shobana, G. Moorkanat, M. Biswas, S. K. Samal, Type I interferon-sensitive recombinant Newcastle disease virus for oncolytic virotherapy. J. Virol. 84, 3835-3844 (2010).
16. V. Schirrmacher, P. Fournier, Newcastle disease virus: A promising vector for viral therapy, immune therapy, and gene therapy of cancer. Methods Mol. Biol. 542, 565-605 (2009).
17. R. S. Bart, A. W. Kopf, J. T. Vilcek, S. Lam, Role of interferon in the anti-melanoma effects of poly (I).poly (C) and Newcastle disease virus. Nat. New Biol. 245, 229-230 (1973).
18. A. L. Pecora, N. Rizvi, G. I. Cohen, N. J. Meropol, D. Sterman, J. L. Marshall, S. Goldberg, P. Gross, J. D. O'Neil, W. S. Groene, M. S. Roberts, H. Rabin, M. K. Bamat, R. M. Lorence, Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J. Clin. Oncol. 20, 2251-2266 (2002).
19. P. Muranski, A. Boni, P. A. Antony, L. Cassard, K. R. Irvine, A. Kaiser, C. M. Paulos, D. C. Palmer, C. E. Touloukian, K. Ptak, L. Gattinoni, C. Wrzesinski, C. S. Hinrichs, K. W. Kerstann, L. Feigenbaum, C. C. Chan, N. P. Restifo, Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 112, 362-373 (2008).
20. + T cells. J. Exp. Med. 198, 569-580 (2003).
21. + B16-F10 melanoma cells. Immunol. Cell Biol. 81, 459-471 (2003).
22. B. Seliger, U. Wollscheid, F. Momburg, T. Blankenstein, C. Huber, Characterization of the major histocompatibility complex class I deficiencies in B16 melanoma cells. Cancer Res. 61, 1095-1099 (2001).
23. O. Hamid, H. Schmidt, A. Nissan, L. Ridolfi, S. Aamdal, J. Hansson, M. Guida, D. M. Hyams, H. Gómez, L. Bastholt, S. D. Chasalow, D. Berman, A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J. Transl. Med. 9, 204 (2011).
24. T. F. Gajewski, J. Louahed, V. G. Brichard, Gene signature in melanoma associated with clinical activity: A potential clue to unlock cancer immunotherapy. Cancer J. 16, 399-403 (2010).
25. A. Marabelle, H. Kohrt, I. Sagiv-Barfi, B. Ajami, R. C. Axtell, G. Zhou, R. Rajapaksa, M. R. Green, J. Torchia, J. Brody, R. Luong, M. D. Rosenblum, L. Steinman, H. I. Levitsky, V. Tse, R. Levy, Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. J. Clin. Invest. 123, 2447-2463 (2013).
26. H. Wilden, P. Fournier, R. Zawatzky, V. Schirrmacher, Expression of RIG-I, IRF3, IFN-β and IRF7 determines resistance or susceptibility of cells to infection by Newcastle disease virus. Int. J. Oncol. 34, 971-982 (2009).
27. H. Kato, S. Sato, M. Yoneyama, M. Yamamoto, S. Uematsu, K. Matsui, T. Tsujimura, K. Takeda, T. Fujita, O. Takeuchi, S. Akira, Cell type-specific involvement of RIG-I in antiviral response. Immunity 23, 19-28 (2005).
28. M. J. Turk, J. A. Guevara-Patiño, G. A. Rizzuto, M. E. Engelhorn, S. Sakaguchi, A. N. Houghton, Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J. Exp. Med. 200, 771-782 (2004).
29. S. A. Quezada, K. S. Peggs, M. A. Curran, J. P. Allison, CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J. Clin. Invest. 116, 1935-1945 (2006).
30. M. A. Curran, W. Montalvo, H. Yagita, J. P. Allison, PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc. Natl. Acad. Sci. U. S. A. 107, 4275-4280 (2010).
31. P. Fournier, A. Arnold, H. Wilden, V. Schirrmacher, Newcastle disease virus induces proinflammatory conditions and type I interferon for counter-acting Treg activity. Int. J. Oncol. 40, 840-850 (2012).
32. L. W. Collison, V. Chaturvedi, A. L. Henderson, P. R. Giacomin, C. Guy, J. Bankoti, D. Finkelstein, K. Forbes, C. J. Workman, S. A. Brown, J. E. Rehg, M. L. Jones, H. T. Ni, D. Artis, M. J. Turk, D. A. Vignali, IL-35-mediated induction of a potent regulatory T cell population. Nat. Immunol. 11, 1093-1101 (2010).
33. K. Franciszkiewicz, A. Boissonnas, M. Boutet, C. Combadière, F. Mami-Chouaib, Role of chemokines and chemokine receptors in shaping the effector phase of the antitumor immune response. Cancer Res. 72, 6325-6332 (2012).
34. D. T. Fisher, Q. Chen, J. J. Skitzki, J. B. Muhitch, L. Zhou, M. M. Appenheimer, T. D. Vardam, E. L. Weis, J. Passanese, W. C. Wang, S. O. Gollnick, M. W. Dewhirst, S. Rose-John, E. A. Repasky, H. Baumann, S. S. Evans, IL-6 trans-signaling licenses mouse and human tumor microvascular gateways for trafficking of cytotoxic T cells. J. Clin. Invest. 121, 3846-3859 (2011).
35. V. Schirrmacher, M. Feuerer, P. Fournier, T. Ahlert, V. Umansky, P. Beckhove, T-cell priming in bone marrow: The potential for long-lasting protective anti-tumor immunity. Trends Mol. Med. 9, 526-534 (2003).
36. J. B. Swann, Y. Hayakawa, N. Zerafa, K. C. Sheehan, B. Scott, R. D. Schreiber, P. Hertzog, M. J. Smyth, Type I IFN contributes to NK cell homeostasis, activation, and antitumor function. J. Immunol. 178, 7540-7549 (2007).
37. I. J. Fidler, Biological behavior of malignant melanoma cells correlated to their survival in vivo. Cancer Res. 35, 218-224 (1975).
38. B. Yaacov, E. Eliahoo, I. Lazar, M. Ben-Shlomo, I. Greenbaum, A. Panet, Z. Zakay-Rones, Selective oncolytic effect of an attenuated Newcastle disease virus (NDV-HUJ) in lung tumors. Cancer Gene Ther. 15, 795-807 (2008).
39. D. Zamarin, P. Palese, Oncolytic Newcastle disease virus for cancer therapy: Old challenges and new directions. Future Microbiol. 7, 347-367 (2012).
40. H. L. Kaufman, D. W. Kim, G. DeRaffele, J. Mitcham, R. S. Coffin, S. Kim-Schulze, Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann. Surg. Oncol. 17, 718-730 (2010).
41. J. Pulido, T. Kottke, J. Thompson, F. Galivo, P. Wongthida, R. M. Diaz, D. Rommelfanger, E. Ilett, L. Pease, H. Pandha, K. Harrington, P. Selby, A. Melcher, R. Vile, Using virally expressed melanoma cDNA libraries to identify tumor-associated antigens that cure melanoma. Nat. Biotechnol. 30, 337-343 (2012).
42. Ipilimumab with or without talimogene laherparepvec in unresected melanoma, ClinicalTrials.gov, NCT01740297 (2013).